G-Quadruplexes Modulate TDP-43 Toxicity in ALS Models

G-quadruplexes (G4s) are non-canonical nucleic-acid structures formed by stacked guanine tetrads. Although they are often studied in the context of genome maintenance and telomeres, G4s also occur in RNA and can influence RNA-binding proteins, translation, and stress responses. The 2025 study by Oldani and colleagues, The effect of G-quadruplexes on TDP43 condensation, distribution, and toxicity, examines whether RNA G4s help determine the behavior of TDP-43, a disease-associated RNA-binding protein implicated in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration.

Study Background and Research Question

TDP-43 normally participates in RNA processing and regulation, with its principal functional pool located in the nucleus. In ALS and related protein-misfolding disorders, however, TDP-43 can redistribute to the cytoplasm and form abnormal inclusions. Aggregation of wild-type TDP-43 is particularly important because it is associated with most sporadic ALS cases, yet the molecular events that initiate or regulate this aggregation remain incompletely defined.

Previous work suggested that RNA can act as a molecular chaperone for TDP-43. Long non-coding RNA, lariat introns, and short TDP-43-binding oligonucleotides have each been reported to alter toxicity or aggregation in experimental systems. TDP-43 also binds G4-containing nucleic acids, and RNA G4s are enriched or remodeled under cellular stress. These observations led Oldani et al. to ask a focused question: do G4s directly alter TDP-43 condensation and aggregation, and can changing G4 stability modify TDP-43 toxicity in cells?

Key Innovation from the Reference Study

The central innovation is the integration of structural RNA biology with a protein-condensation model of neurodegeneration. Rather than treating G4s only as binding sites for TDP-43, the study tests whether they actively shape TDP-43 material states and cellular consequences. This distinction is important because a nucleic acid can affect a protein not only by changing its binding occupancy, but also by changing its concentration, localization, assembly kinetics, or partitioning into stress-associated condensates.

The work is also notable for linking several experimental scales. A biochemical arm tests direct effects on TDP-43 aggregation. Yeast experiments examine whether G4 exposure changes TDP-43 accumulation and cellular tolerance. HEK293T and NSC-34 models then evaluate G4 behavior under proteasomal or oxidative stress, conditions that better approximate the proteostatic challenges relevant to neurodegeneration. According to the reference study, this combined design supports a model in which G4s can redistribute or stabilize TDP-43 in ways that reduce toxic condensation, rather than simply eliminating TDP-43 accumulation.

Methods and Experimental Design Insights

The in vitro experiments used eGFP-tagged TDP-43 with G4 nucleic acids to determine whether G4s could directly modify aggregation in a controlled biochemical setting. This arm is essential because it separates a direct effect of G4 structure on TDP-43 behavior from indirect effects caused by transcriptional changes, stress signaling, or altered cell viability. The reported experiments distinguish DNA G4 testing in the biochemical context from RNA G4-focused observations in cells, an important detail when interpreting structure-specific mechanisms.

In Saccharomyces cerevisiae, the researchers examined TDP-43 accumulation and cellular responses after G4 treatment. The yeast model provides a relatively tractable system for linking protein burden to growth or survival phenotypes. The study found that G4 treatment increased TDP-43 accumulation before cellular death while also increasing tolerance to TDP-43. This apparent separation between abundance and toxicity is mechanistically informative: more intracellular TDP-43 does not necessarily mean a more damaging TDP-43 state.

HEK293T cells expressing TDP-43 were used to evaluate G4-binding small molecules under proteasomal and oxidative stress. These experiments assessed whether ligand-driven increases in G4 stability were accompanied by changes in TDP-43 condensation. The NSC-34 motor-neuron-like model extended the analysis toward a neuronal context. In this system, the study examined G4 and TDP-43 co-localization under stress and measured whether G4-binding compounds altered TDP-43-mediated toxicity.

Protocol Parameters

• Biochemical comparison: Include matched TDP-43 reactions with and without defined G4 substrates so that changes in aggregation can be attributed to the nucleic-acid structure rather than nonspecific nucleic-acid effects.
• Model separation: Treat yeast, HEK293T, and NSC-34 results as complementary rather than interchangeable; each model reports a different relationship among condensation, localization, stress, and toxicity.
• Stress design: Use matched proteasomal-stress, oxidative-stress, and unstressed conditions when testing G4-binding compounds. This helps distinguish stress-dependent rescue from a general reduction in cell activity.
• Readout pairing: Measure TDP-43 condensation or co-localization together with growth, viability, or toxicity. A change in puncta or total accumulation alone cannot establish whether the protein has become more or less harmful.
• Ligand controls: Include vehicle, ligand-only, and G4-structure controls where possible. Structural stabilization, nonspecific aggregation, and cellular stress should be evaluated as separate possibilities.

Core Findings and Why They Matter

G4s directly modulate TDP-43 aggregation

The biochemical experiments show that G4s can modify TDP-43 aggregation in vitro. This is a key result because it establishes that G4-dependent regulation does not require a complete cellular stress response. It also supports a broader view of RNA structure as an active regulator of disease-linked proteins, rather than a passive scaffold for RNA-binding.

G4s reconfigure TDP-43 distribution during stress

In cells, G4s co-localized with TDP-43 condensates under stress conditions. The observation is consistent with a stress-responsive interaction between RNA structure and TDP-43 organization. Importantly, co-localization does not by itself prove that G4s are the cause of a condensate or that every G4-associated assembly is toxic. Instead, it identifies a spatial relationship that can be tested through structure-selective perturbation and orthogonal toxicity measurements.

More TDP-43 can coexist with greater cellular tolerance

Yeast treated with G4s showed increased TDP-43 accumulation before death but also greater tolerance to TDP-43. This finding challenges a simple abundance-based interpretation of proteinopathy. TDP-43 may exist in multiple assemblies or conformational states, with some states being comparatively buffered or less cytotoxic. G4s could therefore influence the partitioning of TDP-43 into assemblies that alter its toxicity without completely preventing accumulation.

G4-binding compounds reduced condensation and toxicity in cell models

In TDP-43-expressing HEK293T cells, G4-binding small molecules increased G4 stability, stabilized TDP-43, and reduced condensation induced by proteasomal or oxidative stress. In NSC-34 cells, related treatment decreased TDP-43-mediated toxicity. Together, these findings suggest that ligand-mediated G4 stabilization can be a useful experimental perturbation for studying TDP-43 proteinopathy. They do not yet establish a therapeutic strategy, but they provide a testable route for determining whether selected RNA structures can buffer disease-associated condensation.

Comparison with Existing Internal Articles

The internal article G-Quadruplexes Modulate TDP-43 Aggregation and Toxicity in ALS Models presents the same study as a broad overview of G4-regulated TDP-43 behavior. The present analysis places greater emphasis on experimental separation: direct biochemical effects, yeast tolerance, stress-associated localization, and ligand responses in mammalian cells. That distinction is useful for researchers deciding which result is most relevant to a planned assay.

A second internal resource, Pyridostatin TFA: Bridging G-Quadruplex Biology to Translational Impact, discusses G4 stabilization in relation to cancer and telomere studies. Its subject overlaps structurally with the present paper but not experimentally: the Oldani study centers on RNA G4s and TDP-43, whereas Pyridostatin-oriented workflows generally address DNA G4 stability and telomere-associated biology. These areas should therefore be connected as related research directions, not treated as interchangeable evidence.

Limitations and Transferability

The study provides mechanistic evidence, but its disease relevance remains provisional. The experiments use overexpression and stress paradigms in yeast and cultured cells rather than patient-derived tissue, animal models, or longitudinal human data. Such systems are valuable for dissecting causality, yet they may exaggerate protein concentration or stress intensity compared with sporadic ALS.

G4 identity is another important limitation. G4s vary in sequence, topology, ligand affinity, cellular location, and folding dynamics. Evidence obtained with defined oligonucleotides cannot automatically be generalized to the full endogenous RNA G4 population. Likewise, a small molecule that stabilizes a G4 may affect multiple RNA structures or cellular pathways. The reported rescue of toxicity should therefore be interpreted alongside controls for ligand selectivity, RNA abundance, TDP-43 expression, and general cytotoxicity.

Finally, the study does not show that Pyridostatin, Pyridostatin TFA, or any particular DNA G4 stabilizer reproduces the reported RNA G4 effects. The strongest conclusion is narrower and more useful: G4 structure is a modifiable variable in TDP-43 condensation and toxicity, and structure-specific ligands can serve as probes for that relationship.

Why this cross-domain matters, maturity, and limitations

The connection between this ALS study and DNA G4 research is scientifically reasonable because both areas investigate how guanine-rich four-stranded structures influence biological processes. In telomere biology research and anticancer drug development, G4 stabilization is commonly used to perturb DNA replication, telomere maintenance, or cancer-cell proliferation. In the TDP-43 study, the relevant question is instead whether RNA G4 stability changes protein condensation and neuronal toxicity. The shared structural theme creates an opportunity for comparative DNA secondary structure research, but it does not remove the need for RNA-specific validation.

This cross-domain bridge is currently hypothesis-generating. A compound validated as a DNA G-quadruplex DNA structure stabilizer may have different cellular distribution, sequence preferences, and off-target effects from the reagents used in the TDP-43 experiments. Researchers should therefore use DNA-directed G4 ligands as comparative tools unless their activity in the relevant RNA G4 and TDP-43 system has been demonstrated directly.

Research Support Resources

For related DNA G4 and telomere workflows, researchers can use Pyridostatin (SKU A3742), commonly handled as Pyridostatin TFA, as a synthetic G4-stabilizing research compound. It may support studies involving G4 structure, telomere biology research, and cancer cell growth inhibitor or anticancer drug development assays, but it should not be assumed to reproduce the RNA G4 effects reported for TDP-43. Follow the linked product information for formulation, handling, and storage, and include structure- and toxicity-specific controls when adapting it to cross-domain experiments.